China Medical System says China approves Desidustat Tablets for renal anaemia

SGX Filings

Yesterday

China Medical System Holdings Limited announced on Mar, 13 2026 that China’s National Medical Products Administration approved Desidustat Tablets, an oral hypoxia-inducible factor-prolyl hydroxylase inhibitor for treating anaemia in non-dialysis adult chronic kidney disease patients.

The company said a China Phase III study showed the drug raised haemoglobin levels versus placebo and maintained target ranges over the long term with acceptable safety, while reducing hepcidin and improving iron metabolism.

Citing more than 120 million chronic kidney disease patients in China and an 8.2% haemoglobin target-achievement rate among non-dialysis anaemia patients, the firm noted significant unmet demand for new treatments.

CMS International Development and Management, a wholly owned subsidiary, holds China rights to the therapy under an exclusive licence signed on Jan, 20 2020 with Zydus Lifesciences.

China Medical System expects Desidustat to complement its existing nephrology product Velphoro and to benefit future financial results.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1197623254"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1197623254\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1197623254?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-13 19:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1197623254","market":"sg","top_or_hot":-1,"title":"China Medical System says China approves Desidustat Tablets for renal anaemia","media":"SGX Filings","content":"<p>China Medical System Holdings Limited announced on Mar, 13 2026 that China’s National Medical Products Administration approved Desidustat Tablets, an oral hypoxia-inducible factor-prolyl hydroxylase inhibitor for treating anaemia in non-dialysis adult chronic kidney disease patients.</p>\n<p>The company said a China Phase III study showed the drug raised haemoglobin levels versus placebo and maintained target ranges over the long term with acceptable safety, while reducing hepcidin and improving iron metabolism.</p>\n<p>Citing more than 120 million chronic kidney disease patients in China and an 8.2% haemoglobin target-achievement rate among non-dialysis anaemia patients, the firm noted significant unmet demand for new treatments.</p>\n<p>CMS International Development and Management, a wholly owned subsidiary, holds China rights to the therapy under an exclusive licence signed on Jan, 20 2020 with Zydus Lifesciences.</p>\n<p>China Medical System expects Desidustat to complement its existing nephrology product Velphoro and to benefit future financial results.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Medical System says China approves Desidustat Tablets for renal anaemia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Medical System says China approves Desidustat Tablets for renal anaemia\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1083912268\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/57d1beae95c40ebe9f2698a436562e39);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">SGX Filings </p>\n<p class=\"h-time\">2026-03-13 19:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>China Medical System Holdings Limited announced on Mar, 13 2026 that China’s National Medical Products Administration approved Desidustat Tablets, an oral hypoxia-inducible factor-prolyl hydroxylase inhibitor for treating anaemia in non-dialysis adult chronic kidney disease patients.</p>\n<p>The company said a China Phase III study showed the drug raised haemoglobin levels versus placebo and maintained target ranges over the long term with acceptable safety, while reducing hepcidin and improving iron metabolism.</p>\n<p>Citing more than 120 million chronic kidney disease patients in China and an 8.2% haemoglobin target-achievement rate among non-dialysis anaemia patients, the firm noted significant unmet demand for new treatments.</p>\n<p>CMS International Development and Management, a wholly owned subsidiary, holds China rights to the therapy under an exclusive licence signed on Jan, 20 2020 with Zydus Lifesciences.</p>\n<p>China Medical System expects Desidustat to complement its existing nephrology product Velphoro and to benefit future financial results.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"8A8.SI","symbol_name":"康哲药业控股有限公司","start_time":0,"source_url":"","article_id":"1197623254","we_media_id":"1083912268","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1197623254","pubTimestamp":1773400142,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"SGX Filings","introduction":"Fastest News on SGX Filings ","home_visible":1,"id":"1083912268","head_image":"https://community-static.tradeup.com/news/57d1beae95c40ebe9f2698a436562e39"},"summary":"China Medical System Holdings Limited announced on Mar, 13 2026 that China’s National Medical Products Administration approved Desidustat Tablets, an oral hypoxia-inducible factor-prolyl hydroxylase...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"8A8.SI":"康哲药业控股有限公司"},"translate_title":"康哲药业称中国批准Desidustat片治疗肾性贫血","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"8A8.SI":1},"content_text":"China Medical System Holdings Limited announced on Mar, 13 2026 that China’s National Medical Products Administration approved Desidustat Tablets, an oral hypoxia-inducible factor-prolyl hydroxylase inhibitor for treating anaemia in non-dialysis adult chronic kidney disease patients.\nThe company said a China Phase III study showed the drug raised haemoglobin levels versus placebo and maintained target ranges over the long term with acceptable safety, while reducing hepcidin and improving iron metabolism.\nCiting more than 120 million chronic kidney disease patients in China and an 8.2% haemoglobin target-achievement rate among non-dialysis anaemia patients, the firm noted significant unmet demand for new treatments.\nCMS International Development and Management, a wholly owned subsidiary, holds China rights to the therapy under an exclusive licence signed on Jan, 20 2020 with Zydus Lifesciences.\nChina Medical System expects Desidustat to complement its existing nephrology product Velphoro and to benefit future financial results.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}